Predictive Oncology Yönetim

Yönetim kriter kontrolleri 0/4

Predictive Oncology CEO'su Raymond Vennare, Nov2022 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 638.58K olup, şirket hissesi ve opsiyonları dahil olmak üzere 13.7% maaş ve 86.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.18% ine doğrudan sahiptir ve bu hisseler € 40.14K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.4 yıl ve 2.4 yıldır.

Anahtar bilgiler

Raymond Vennare

İcra Kurulu Başkanı

US$638.6k

Toplam tazminat

CEO maaş yüzdesi	13.7%
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.4yrs
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Raymond Vennare'un ücretlendirmesi Predictive Oncology'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$639k	US$88k	-US$26m
Sep 30 2022	n/a	n/a	-US$26m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$33k	n/a	-US$20m

Tazminat ve Piyasa: Raymond 'nin toplam tazminatı ($USD 638.58K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 483.75K ).

Tazminat ve Kazançlar: Raymond şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Raymond Vennare (70 yo)

less than a year

Görev süresi

US$638,578

Tazminat

Mr. Raymond F. Vennare is Chief Executive Officer and Chairman at Predictive Oncology Inc. from November 01, 2022. He Co-Founded ThermalTherapeutic Systems, Inc. in 2006 and served as its Executive Vice Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Raymond Vennare	CEO & Chairman	less than a year	US$638.58k	0.18% € 40.1k
Robert Myers	CFO & Secretary	11.6yrs	US$511.87k	0.089% € 20.1k
Theresa Ferguson	Senior Director of Marketing	1.3yrs	Veri yok	Veri yok
Pamela Bush	Chief Business Officer	1.6yrs	Veri yok	0.059% € 13.4k
Lawrence DeLucas	Senior Vice President of Biologics	no data	Veri yok	Veri yok
Arlette Uihlein	Senior VP of Translational Medicine & Drug Discovery and Medical Director	no data	Veri yok	Veri yok

1.4yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim: S1K 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.4 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Raymond Vennare	CEO & Chairman	1.8yrs	US$638.58k	0.18% € 40.1k
Bernard Harris	Member of Business Advisory Board	less than a year	Veri yok	Veri yok
Charles Nuzum	Lead Independent Director	3yrs	US$140.56k	Veri yok
Andrew Einhorn	Member of Business Advisory Board	less than a year	Veri yok	Veri yok
Veena Rao-Mirmira	Director	less than a year	Veri yok	0.099% € 22.4k
Marc Malandro	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Daniel Handley	Independent Director	3.4yrs	US$73.89k	0.32% € 72.1k
Robert Murphy	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Matthew Hawryluk	Director	less than a year	US$8.33k	0.13% € 29.6k
Nancy Chung-Welch	Independent Director	3yrs	US$118.34k	0.38% € 85.0k
Gregory St. Clair	Independent Director	3yrs	US$85.00k	0.40% € 90.5k
Christoph Reinhard	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: S1K 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Predictive Oncology Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

High number of new and inexperienced directors

Recent updates

Predictive Oncology Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

Predictive Oncology Inc. Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Predictive Oncology Inc. Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Inc. to Report Q2, 2024 Results on Aug 14, 2024

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Predictive Oncology Inc. has filed a Follow-on Equity Offering in the amount of $3.696 million.

Predictive Oncology Inc. to Report Q1, 2024 Results on May 15, 2024

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought €59k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.051 loss per share (vs US$0.11 loss in 1Q 2021)

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings released: US$0.36 loss per share (vs US$2.21 loss in FY 2020)

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.

New 90-day high: €1.30

Predictive Oncology Announces the Start of Its Drug Repurposing Project Using Its Ground-Breaking Pedal™ Platform for Ovarian Cancer

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $4.097964 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $2.2 million.

New 90-day high: €0.89

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $3.074007 million.

New 90-day high: €0.73

Third quarter 2020 earnings released: US$0.46 loss per share

New 90-day low: €0.49

Predictive Oncology Receives A Letter from the Listing Qualifications Department Nasdaq Stock Market

Predictive Oncology Inc. announced that it has received $1.370002 million in funding

Precision Therapeutics Inc. Announces Executive Appointments

New 90-day low: €0.61

Predictive Oncology Inc. (NasdaqCM:POAI) completed the acquisition of Assets of Quantitative Medicine, LLC for $2.6 million.

Predictive Oncology Inc. (NasdaqCM:POAI) entered into a letter of intent to acquire Assets of Quantitative Medicine, LLC.